La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BerGenBio Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Martin Olin

Amministratore delegato

NOK 10.2m

Compenso totale

Percentuale dello stipendio del CEO	51.5%
Mandato del CEO	3yrs
Proprietà del CEO	0.08%
Durata media del management	2.9yrs
Durata media del Consiglio di amministrazione	1.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Martin Olin rispetto agli utili di BerGenBio?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-NOK 155m
Mar 31 2024	n/a	n/a	-NOK 155m
Dec 31 2023	NOK 10m	NOK 5m	-NOK 190m
Sep 30 2023	n/a	n/a	-NOK 226m
Jun 30 2023	n/a	n/a	-NOK 258m
Mar 31 2023	n/a	n/a	-NOK 293m
Dec 31 2022	NOK 11m	NOK 5m	-NOK 302m
Sep 30 2022	n/a	n/a	-NOK 294m
Jun 30 2022	n/a	n/a	-NOK 304m
Mar 31 2022	n/a	n/a	-NOK 309m
Dec 31 2021	NOK 4m	NOK 1m	-NOK 309m

Compensazione vs Mercato: La retribuzione totale di Martin ($USD 969.36K ) è superiore alla media delle aziende di dimensioni simili nel mercato Norwegian ($USD 300.00K ).

Compensazione vs guadagni: La retribuzione di Martin è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Martin Olin (55 yo)

3yrs

Mandato

NOK 10,231,670

Compensazione

Mr. Martin Olin serves as Chief Executive Officer at BerGenBio ASA since September 8, 2021. Mr. Olin has been Chairman of the Board at AcouSort AB (publ) since April 28, 2021. He has experience from execut...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Martin Olin	Chief Executive Officer	3yrs	NOK 10.23m	0.078% NOK 292.6k
Rune Skeie	Chief Financial Officer	6.5yrs	NOK 3.59m	0.010% NOK 37.5k
Cristina Oliva	Chief Medical Officer	2.4yrs	NOK 5.70m	Nessun dato
Graham Morell	Head of IR	no data	Nessun dato	Nessun dato
Gayle Mills	Chief Business Officer	2.8yrs	NOK 3.39m	Nessun dato
Akil Jackson	Medical Director	no data	Nessun dato	Nessun dato

2.9yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di BGBIO è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sally Bennett	Independent Non-Executive Director	3.8yrs	NOK 358.00k	0.012% NOK 45.5k
John Heymach	Member of Scientific Advisory Board	1.6yrs	Nessun dato	Nessun dato
Shu Kam Mok	Member of Scientific Advisory Board	1.6yrs	Nessun dato	Nessun dato
Debra Barker	Independent Non-Executive Director	5.5yrs	NOK 344.00k	0.012% NOK 44.9k
Anders Tullgren	Independent Chairman of the Board	2.7yrs	NOK 848.00k	0.055% NOK 208.6k
Enriqueta Font	Member of Scientific Advisory Board	1.6yrs	Nessun dato	Nessun dato
Solange Peters	Member Scientific Advisory Board	1.6yrs	Nessun dato	Nessun dato

1.6yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di BGBIO non è considerato esperto (durata media del mandato 1.5 anni), il che suggerisce un nuovo consiglio.

BerGenBio Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Executive Officer exercised options to buy kr323k worth of stock.

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

High number of new and inexperienced directors

BerGenBio ASA Announces Board Appointments

Chairman of the Board recently bought kr268k worth of stock

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

Recent updates

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Price target decreased by 63% to kr5.68

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

Chief Executive Officer exercised options to buy kr323k worth of stock.

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

Price target decreased to kr12.00

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

BerGenBio ASA Provides Update on Clinical Development

Chairman of the Board recently bought kr268k worth of stock

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Consensus forecasts updated

Price target decreased to kr47.50

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Chief Executive Officer recently bought kr204k worth of stock

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

New 90-day low: kr30.75

Analysts update estimates

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Revenue and earnings in line with expectations

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

Price target raised to kr63.00

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

New 90-day high: kr37.30

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

New 90-day high: kr36.00

BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020

BerGenBio ASA Confirms First Patient Enrolled in Phase II Trial Assessing Bemcentinib as Potential Treatment for COVID-19 in India

Earnings beat expectations

BerGenBio ASA Presents Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

New 90-day low: kr28.20